FindTrial
Sign In

Clinical role of 11C-methionine PET/CT in renal cell carcinoma

Clinical role of 11C-methionine PET/CT in renal cell carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006218
Enrollment
50
Registered
2021-06-02
Start date
2016-09-12
Completion date
Unknown
Last updated
2021-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Yonsei University Health System, Severance Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Patients with clinically suspected primary kidney cancer (renal cell carcinoma) 2) Patients undergoing diagnostic tests for staging after being confirmed as primary kidney cancer 3) Patients planning nephrectomy due to suspected kidney cancer 4) The age allowed to participate in the study is adults between 20 and 90 years old.

Exclusion criteria

Exclusion criteria: 1) Patients suspected of having metastatic cancer other than primary renal cancer or diagnosed with metastatic cancer 2) Patients diagnosed with benign tumors other than primary kidney cancer 3) Pregnant patients, nursing mothers 4) children

Design outcomes

Primary

MeasureTime frame
Tumor Stage Prediction—

Secondary

MeasureTime frame
Overall survival and Progression free survival—

Countries

Korea, Republic of

Contacts

Public ContactDongwoo Kim

Yonsei University Health System, Severance Hospital

kdwoo@yuhs.ac+82-2-2228-4855

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026